Analyst - S2P Operational Excellence
Novo Nordisk is hiring an Analyst for their Global Business Services (GBS) team to drive transformation projects in procurement and finance. The role involves managing cross-functional initiatives, leading UAT, and creating strategic presentations for senior leadership. Candidates require significant experience in finance operations and project management. This position is based in Bengaluru and focuses on streamlining global business services.
50k new jobs listed every day. Install TAL to find more jobs like this.
Experience
6-8 years
Function
Operations
Work mode
Onsite, India
Company
Tier 2
What you will work on
Novo Nordisk is hiring an Analyst for their Global Business Services (GBS) team to drive transformation projects in procurement and finance. The role involves managing cross-functional initiatives, leading UAT, and creating strategic presentations for senior leadership. Candidates require significant experience in finance operations and project management. This position is based in Bengaluru and focuses on streamlining global business services.
TAL's take
Solid role at a globally recognized healthcare leader, though specific to GBS operations rather than core technical R&D.
Highly specific JD outlining project management, UAT, and operational excellence responsibilities within finance.
Salaries at Novo Nordisk
19.3 LPA average
Based on 19 Grapevine salary entries for Novo Nordisk.
Operations
4 - 6 years | L5
10 LPA average
Range: 10 - 10 LPA
Other roles
0 - 2 years
4 LPA average
Range: 4 - 4 LPA
Product Management
2 - 4 years | 6
14 LPA average
Range: 14 - 14 LPA
Other roles
2 - 4 years | 6
17 LPA average
Range: 17 - 17 LPA
Must haves
- 6-8 years experience from a finance BPO center
- 5+ years work experience in Accounts Payable or similar finance operations
- Minimum 3+ years of project management experience
- Strong project management skills
- Excellent oral and written communication skills
- Experience in designing high-quality PowerPoint presentations
Tools and skills
Nice to have: photoshop, coreldraw.
About the company
Global healthcare company, but GBS role is a functional support unit rather than core engineering/product.
Posts mentioning Novo Nordisk
Amgen's Weight-Loss Drug Falls Short, Stock Plummets
- Amgen's MariTide Phase-2 data showed 20% weight loss at 52 weeks, but stock dropped 13.31% pre-market. - Rival stocks Eli Lilly and Novo Nordisk rose on Biden's proposal for expanded Medicare, Medicaid coverage for obesity drugs. - Retail investors remain bullish on Amgen despite analyst disappointment. Source: [Asianet Newsable](https://newsable.asianetnews.com/markets/amgen-stock-sinks-on-modest-obesity-drug-results-but-retail-sentiment-remains-steady-snk9xh), [Asianet Newsable](https://newsable.asianetnews.com/markets/eli-lilly-novo-nordisk-shares-climb-premarket-as-biden-administration-mulls-medicare-medicaid-covering-for-obesity-drugs-retail-unmoved-snk72g)
The Controversial Rise of Weight Loss Drugs
- Weight loss drugs like OIC, Zep bound, and Monaro are becoming increasingly popular, despite high costs. - These drugs, also known as glucagon-like peptide one drugs, mimic a natural hormone that affects brain signals on appetite and hunger. - The potential market for obesity medication is massive, with some speculating it could be more lucrative than any other class of drug. - Pharmaceutical companies are pushing for obesity to be classified as a disease, which could open up a market worth trillions of dollars. - However, there are concerns about the ethics of these companies, particularly given the history of the opioid epidemic. - Companies like Eli Lily and Novo Nordisk are leading the way in this new class of drugs, with their share prices and market caps increasing significantly. Source: [Modern MBA](https://www.youtube.com/watch?v=7sUoZVke_30&ab_channel=ModernMBA)
The Looming Fiscal Crisis Over Revolutionary Weight Loss Drugs
- America faces a fiscal crisis over revolutionary weight loss drugs like Ozempic and Wegovy. - These drugs, produced by Novo Nordisk, have potential cardiovascular, mental health, and anti-cancer benefits. - However, their high cost in the U.S. compared to other countries could bankrupt Medicare. - If half of U.S. adults with obesity took these drugs, it would cost $411 billion annually. - The State Treasurer of North Carolina, Dale Folwell, is questioning the high cost and has asked the federal government to negotiate with Novo Nordisk to open up patents to generic manufacturers. Source: [More Perfect Union](https://youtu.be/JqHmvMjXuro)